Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01348126 · ClinicalTrials.gov registry record · Phase 2
Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer
A Phase 2 study, sponsored by Synta Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 385
- Enrollment target
NCT01348126: Clinical Trial Phase 2 study, sponsored by Synta Pharmaceuticals.
NCT01348126 is a Phase 2 study that was terminated before completion, run by Synta Pharmaceuticals. The registered enrollment target is 385 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01348126, a Phase 2 study, was terminated before completion, sponsored by Synta Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 385 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether combining ganetespib (STA-9090) with docetaxel is more effective than docetaxel alone in the treatment of subjects with advanced non-small cell lung cancer.
Interventions
- DRUG Docetaxel
- DRUG Combination of ganetespib and docetaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 385 participants |
| Start Date | 2011-05 |
| Est. Completion | 2015-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01348126
The ClinicalTrials.gov registry entry for NCT01348126 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 385 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Synta Pharmaceuticals, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Docetaxel is the first listed.
NCT01348126 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01348126 about?
NCT01348126 is a clinical study titled "Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer". The purpose of this study is to determine whether combining ganetespib (STA-9090) with docetaxel is more effective than docetaxel alone in the treatment of subjects with advanced non-small cell lung cancer.
What is the current status of trial NCT01348126?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 385 participants. The study started on 2011-05. Estimated completion is 2015-10.
What interventions are being tested in trial NCT01348126?
The interventions under investigation include: Docetaxel (DRUG), Combination of ganetespib and docetaxel (DRUG).
Who is sponsoring clinical trial NCT01348126?
This trial is sponsored by Synta Pharmaceuticals, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.